Results 201 to 210 of about 24,222,086 (313)

The Cytoplasmic Domain of Syndecan-1 Is Required for Cytoskeleton Association but Not Detergent Insolubility [PDF]

, 1996
David J. Carey, Katharine M. Bendt, Richard C. Stahl   +2 more
openalex   +1 more source

Syndecan-1 in Liver Diseases

Liver diseases such as liver cirrhosis, primary and metastatic liver cancers are still a major medical challenge. Syndecan-1 is one of the most important proteoglycans in the liver. Syndecan-1 is normally expressed on the surfaces of hepatocytes and cholangiocytes. Due to liver diseases the amount of syndecan-1 increases in the liver.
Regős E, Karászi K, Reszegi A, Kiss A, Schaff Zs, Baghy K, Kovalszky I   +6 more
openaire   +1 more source

Association Between Serum Syndecan 1 Levels and Metabolic Syndrome Parameters: A Comparative Cross-Sectional Study. [PDF]

Endocrinol Diabetes Metab
Tavalaie S, Darroudi S, Shabani N, AzadAra A, Mottaghi-Moghaddam A, Rahmani MK, Mohammadi-Bajgiran M, Ferns GA, Saberi-Karimian M, Ghayour-Mobarhan M.   +9 more
europepmc   +1 more source

The Intensity and Pattern of Syndecan-1 (CD138) Expression in Normal and Diseased Livers. [PDF]

Cureus, 2023
Atique M, Javed R, Seerat I, Atique U, Bhatti T.   +4 more
europepmc   +1 more source

Syndecan‐1 is Associated With Sinusoidal Obstruction Syndrome and Severe Acute Graft‐Versus‐Host Disease After Pediatric Hematopoietic Stem Cell Transplantation [PDF]

Denise Elbæk Horan, Sarah Weischendorff, Pär I. Johansson, Marianne Ifversen, Claus Henrik Nielsen, Klaus Müller, Katrine Kielsen   +6 more
openalex   +1 more source

Targeting Prostate Cancer Cells Using Anti-Sortilin and Anti-Syndecan-1 Antibody Drug Conjugates. [PDF]

Int J Mol Sci
Li KL, Hickey SM, Albrecht H, Logan JM, Lazniewska J, Moore CR, Brooks RD, Johnson IRD, O'Leary JJ, Brooks DA.   +9 more
europepmc   +1 more source

Investigation of the relationship between intradialytic hypotension during hemodialysis and serum syndecan-1 concentration. [PDF]

Sci Rep, 2023
Oiwa H, Okada H, Suzuki K, Sumi K, Yoshida S, Suzuki K, Ishihara T, Kitagaki H, Kimura K, Naito Y, Chiba N, Kuroda A, Uchida A, Fukuda H, Kawasaki Y, Minamiyama T, Nishio A, Shimada T, Kamidani R, Miura T, Tochibora R, Yamamoto S, Kinomura Y, Kitagawa Y, Fukuta T, Miyake T, Yoshida T, Suzuki A, Tetsuka N, Tomita H, Nawa T, Ogura S.   +31 more
europepmc   +1 more source

Prognostic impact of syndecan-1 expression and serum concentration in colorectal cancer. [PDF]

Oncol Lett
Tawada K, Hayashi H, Endo M, Horaguchi T, Yokoi R, Matsumoto K, Kuno M, Fukada M, Asai R, Sato Y, Yasufuku I, Tajima JY, Tanaka Y, Takahashi T, Matsuhashi N, Tomita H.   +15 more
europepmc   +1 more source

Significance of the syndecan-4-transglutaminase-2 interaction [PDF]

, 2010
Scarpellini, A, Verderio, E
core   +2 more sources

Methamphetamine-Induced Loss of Syndecan-1 and Retinal Endothelial Integrity via the TAAR-1/MMP-9 Pathway. [PDF]

Pathophysiology
Lee M, Ha T, Alvarez IA, Leskova W, Park C, Harris NR.   +5 more
europepmc   +1 more source